

## CONTENTS OF VOLUME 2

### PHARMACOLOGY AND THERAPEUTIC RADIOPHARMACEUTICALS (SESSION 8)

Biological and chemical evaluation of various radio colloids used for clinical radio synovectomy .....	3
<i>G.A. Ianoki, L. Balogh, A. Polyak, D. Mathe, K. Korosi, R. Kiraly</i>	
Targeted radiotherapy with alpha particle emitting radionuclides .....	25
<i>M.R. Zalutsky, O.R. Pozzi, G. Vaidyanathan</i>	
DOTA-Tyr3-octreotide labelled with $^{177}\text{Lu}$ and $^{131}\text{I}$ .....	39
<i>V. Lungu, D. Niculae, D. Chiper, M Radu</i>	
177Lu-labelled nitroimidzoles and nitrotriazoles for possible use in targeted therapy of hypoxic tumours. ....	51
<i>T. Das, S. Chakraborty, A. Mukherjee, S. Banerjee, G. Samuel, H.D. Sarma, M. Venkatesh</i>	
Labelling and biological evaluation of anti-CD20 for treatment of non-Hodgkin's lymphoma. ....	63
<i>P. Oliver, A. Robles, V. Trindade, P. Cabral, V. Tortarolo, A. Nappa, G. Rodriguez, H Balter</i>	

### THERAPEUTIC RADIOPHARMACEUTICALS (SESSION 9)

177Lu-DOTA-J591 monoclonal antibody: Chemistry, toxicity, dosimetry and clinical efficacy .....	73
<i>S.I. Goldsmith, S. Vallabhajosula, Ml. Milowsky, D.M Nanus, N.H Bander</i>	
Radiolabelled somatostatin analogues for radionuclide therapy of tumours. ....	91
<i>M. delong, D. Kwekkeboom, R. Valkema, E. Krenning</i>	
Iodine whole body scan, thyroglobulin levels, $^{99\text{m}}\text{TcMIBI}$ scan and computed tomography. ....	109
<i>N.o. Kuruk, S.S. Gultekin, G. Aras, E. ihis</i>	

99mTc-MIBI and $^{131}\text{I}$ scintigraphy in the follow-up of differentiated thyroid carcinoma (DTC) patients after surgery. ....	123
<i>S. Sergieva, T. Hadjieva, V. Botev, A. Dudov</i>	

Results of knee radiosynoviorthesis in haemophilic and rheumatoid arthritic patients with $^{32}\text{P}$ colloid of local production .....	135
<i>V.E. Soroa, M.H. Velazquez Espeche, C. Giannone, G. Naswetter, H. Caviglia, G. Galatros</i>	

## PET RADIO PHARMACEUTICALS (SESSION 10)

Alternative methods of making [ $^{11}\text{C}$ ]amides: Application to the preparation of 5-HT <sub>1A</sub> receptor radioligands. ....	147
<i>V.W. Pike, S.Y. Lu, J. Hong, J.L. Musachio, J.A. McCarron</i>	

FSF]fluoroethylated and [ $^{11}\text{C}$ ]methylated PET tracers for research and routine diagnosis .....	161
<i>M. Mitterhauser, W. Wadsak</i>	

A novel finding: Anti-androgen flutamide kills androgen independent PC-3 cells. ....	183
<i>F. Al-Saeedi</i>	

A semi-automated $[^{13}\text{N}]NH_3$ production module: Design, quality control and optimization. ....	195
<i>AR. Jalilian, P. Rowshanfarzad, M. Sabet, M. Mirzaii, A. Ziaeef, D. Sardari</i>	

## RADIOIODINE RADIOPHARMACEUTICALS (SESSION 11)

Production of radioiodines with medical PET cyclotrons .....	209
<i>J.J. Comor, G.-J. Beyer, G. Pimentel-Gonzales</i>	

New developments in radio iodinated radiopharmaceuticals for SPECT and radionuclide therapy: $[^{123}\text{I}]/[^{131}\text{I}]$ -labelled L- and D-phenylalanine analogues. ....	223
<i>M. Bauwens, J.J.R. Mertens, T. Lahoutte, K. Kersemans, C. Gallez, A. Bossuyt</i>	

Comparison of $^{131}\text{I}$ -TYR3-octreotate and $^{131}\text{I}$ -DOTA-TYR3-octreotate: The effect of DOT A on pharmacokinetics and stability. ....	243
<i>E.B. de Araujo, E. Muramoto, L.T. Nagamati, f.S. Caldeira Filho, R.M. Couto, c.P.G. Silva</i>	
Iodine labelled diethylstilbestrol (DES) of high specific activity: A potentital radiopharmaceutical for therapy of estrogen receptor positive tumours and their metastases? .....	253
<i>T. Fischer, H. Schicha, K. Schomacker</i>	
<b>18FRADIO PHARMACEUTICALS AND AUTOMATION OF SYNTHESIS (SESSION 12)</b>	
ISpbased radiopharmaceuticals and automation of synthesis. ....	265
<i>P.K. Garg, S. Garg</i>	
Rapid method for radiotluorination of pyridine derivatives: Prosthetic groups for labelling bioactive molecules. ....	283
<i>I. Al fammaz, B. Al Otaibi, H. Ravert, f. Amartey</i>	
1-PSp]tluoroeth ylene glycol-2-nitroimidazoles: A novel class of potential hypoxia PET markers. ....	295
<i>R.I. Abdel-falil, M. Obele, W. Ehrlichmann, W. Voelter, H.-f. Machulla</i>	
Radiosynthesis and in vivo evaluation in melanoma-bearing mice of O-(2-PSp]tluoroethyl)-L-tyrosine as a tumour tracer. ....	297
<i>Mingwei Wang, Duanzhi Yin, Yongxian Wang</i>	
<b>CYCLOTRON BASED RADIONUCLIDES AND GENERATORS (SESSION 13)</b>	
Production of radionuclides with a cyclotron. ....	311
<i>D.I. Schlyer</i>	
Perspectives for the large scale production of radiolanthanides with medical potential. ....	331
<i>G.-f. Beyer, H.L. Ravn, U. Koster</i>	
Production of $^{123}\text{I}$ _MIBGIPEN-CNEN/SP .....	349
<i>M.P. de Barboza, V. Sciani, R. Herreras, M.M.N. Matsuda,</i>	

*N.T.O. Fukumori, L.CA Sumiya, H. Matsuda, AA Souza,  
MM Goes, J.T. Pires, J. Mengatti, CP. Gomez da Silva*

A new 82Sr_82Rbgenerator. ....	353
<i>A Bilewicz, B. Bartos, R. Misiak, B. Petelenz</i>	
Cyclotron production of 103Pdvia proton induced reactions on a 103Rhtarget. ....	357
<i>M Sadeghi, H. Afarideh, G. Raisali, M Haji-Saeid</i>	
The status and potential of new radionuclide generators providing positron emitters to synthesize new targeting vectors for PET ....	367
<i>F. Roesch, KP. Zhernosekov, D.V. Filosofov, M. Jahn, M. Jennewein</i>	
<b>RADIO PHARMACY (SESSION 14)</b>	
Nuclear pharmacy practices in the United States of America .....	385
<i>K Ozker</i>	
Regulatory aspects of hospital radiopharmacy and clinical trials. ....	391
<i>AA Soylu</i>	
Standardization and quality control of an in-house formulation of 99mTc(V)-DMSA in tumour imaging and assessment of tumour biology: Work in progress. ....	399
<i>P.S. Choudhury, N.C Goomer, A Gupta, D.C Doval, T. Kataria, AK Vaid, P.K Sharma</i>	
Development of centralized radiopharmacies in Spain: A successful experience in Europe. ....	413
<i>I. Oyarzabal, R. Jimenez-Shaw</i>	
Chairpersons of Sessions. ....	421
Secretariat of the Symposium. ....	422
Programme Committee ... ,.....	422
List of Participants. ....	423
Author Index. ....	461